Clinical relevance of residual disease monitoring by polymerase chain reaction in patients with ALL-1/AF-4 positive-acute lymphoblastic leukaemia

Giuseppe Cimino, Loredana Elia, Anna Rivolta, Maria Cristina Rapanotti, Vincenzo Rossi, Giuliana Alimena, Luciana Annino, Eli Canaani, Francesco Lo Coco, Andrea Biondi

Research output: Contribution to journalArticle

Abstract

In this study we used reverse transcriptase-polymerase chain reaction (RT-PCR) for the longitudinal monitoring of minimal residual disease in 12 patients with ALL 1/AF-4 positive ALL. Of these, seven also showed at presentation a typical t(4;11) cytogenetic translocation. Seven patients were infants <18 months of age and five were adults. Eleven patients were treated with high-dose intensive induction and consolidation chemotherapy without bone marrow transplantation and one received conservative treatment due to poor performance status. Three had resistant disease, four relapsed within 12 months after achieving complete remission, and five are in continuous complete remission (CCR) at 32, 39, 52, 53 and 61 months from diagnosis, respectively. The sequential analysis of the ALL-1/AF-4 hybrid transcript showed a persistently negative RT-PCR in the five CCR long-term survivors. The PCR analysis resulted persistently positive in the remaining seven cases, including the four cases who relapsed after the achievement of clinical CR. These data emphasize the clinical relevance of PCR monitoring analysis in t(4;11) ALL patients and should be considered in order to better determine variable postremission treatment according to risk prediction.

Original languageEnglish
Pages (from-to)659-664
Number of pages6
JournalBritish Journal of Haematology
Volume92
Issue number3
Publication statusPublished - 1996

Keywords

  • Acute lymphoblastic leukaemia
  • Minimal residual disease
  • RT-PCR
  • t(4,11)

ASJC Scopus subject areas

  • Hematology

Fingerprint Dive into the research topics of 'Clinical relevance of residual disease monitoring by polymerase chain reaction in patients with ALL-1/AF-4 positive-acute lymphoblastic leukaemia'. Together they form a unique fingerprint.

  • Cite this